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Association Between the 1291-C/G Polymorphism in the
Adrenergic >-2a Receptor and the Metabolic Syndrome
Arne J. Risselada, PharmD,*Þ Jelle Vehof, MD,þ§ Richard Bruggeman, MD, PhD,þ
Bob Wilffert, PharmD, PhD,|| Dan Cohen, MD, PhD,¶ Asmar F. Al Hadithy, PharmD, PhD,||L
Johan Arends, MD,** and Hans Mulder, PharmD, PhD*Þ
Abstract: The prevalence of the metabolic syndrome is increased in
patients with schizophrenia compared with the general population. The
strong interindividual differences in susceptibility to developing the
metabolic syndrome suggests that the genetic makeup is a modulating
factor. Part of the genetic puzzle can possibly be explained by variations
in the gene coding for the adrenergic >-2a receptor (ADRA2A) because
this receptor plays an important role in lipolysis.
Three studies have found an association between the >-2a 1291-C/G
polymorphism and antipsychotic induced weight gain, with conﬂicting
results between whites and Asians. No studies have been published in-
vestigating the association between the 1291-C/G polymorphism and the
metabolic syndrome.
The primary objective of this cross-sectional study was to investigate
the association between the ADRA2A 1291-C/G polymorphism and the
metabolic syndrome in 470 patients using antipsychotic drugs.
There was no signiﬁcant association between carriership of the var-
iant 1291-G allele and prevalence of the metabolic syndrome (odds
ratio, 0.73; 95% conﬁdence interval, 0.49Y1.15). Exploratory analysis
showed an association between carriership of the variant 1291-G allele
and a reduced prevalence of the metabolic syndrome in patients not
currently using antipsychotics (odds ratio, 0.05; 95% conﬁdence interval,
0.003Y0.97; P = 0.048).
In conclusion, this study shows that the ADRA2A 1291-C/G poly-
morphism does not seem to be a strong predictor for long-term occur-
rence of the metabolic syndrome in antipsychotic using patients. Studies
investigating this association using a prospective, or retrospective, de-
sign, as well as studies investigating this association in a nonpsychiatric
population, are warranted.
Key Words: ADRA2A, antipsychotics, metabolic syndrome,
schizophrenia, 1291-C/G
(J Clin Psychopharmacol 2010;30: 667Y671)
I t has been shown that the prevalence of the metabolic syn-drome is increased in patients with schizophrenia compared
with the general population.1 Although controversy exists about
the causal mechanisms, it is most likely that metabolic adverse
effects of antipsychotic drugs including lipid abnormalities,
disturbed glucose metabolism, and weight gain are important
determinants for this increased prevalence. These metabolic
disturbances, like insulin resistance, can still be present for
more than a year after treatment with the antipsychotic drugs
has ended.2
The mechanism behind antipsychotic-induced metabolic
abnormalities is not entirely clear. The high interindividual dif-
ferences suggest that genetic makeup is a modulating factor.
One of the potential genetic determinants is genetic varia-
tion in the gene coding for the adrenergic >-2 receptor, because
of its effects on the breakdown of fat (lipolysis) and the fact that
antipsychotics such as clozapine, which are associated with met-
abolic abnormalities, have a high afﬁnity for the >-2 receptors.
Studies have shown that stimulation of the G proteinYcoupled >-2
adrenergic receptor leads to an inhibition of lipolysis.3Weight loss
during hypocaloric diets was associated with a decreased >-2
adrenoceptor sensitivity.4
Three different subtypes of the >-2 adrenoceptor have been
discovered: >-2a, >-2b, and >-2c.5 Data from the HERITAGE
Family study showed an association between the 1291-C/G
polymorphism (rs1800544) in the gene coding for the >-2a re-
ceptor (ADRA2A) and accumulation of (predominantly abdom-
inal) body fat.6 Black male patients carrying the variant 1291-G
allele had a higher trunk-to-extremity skin fold ratio than black
male patients without the variant allele. No association was
found in white subjects. Recently, overexpression of the >-2a
receptor and the rs553668 polymorphism in the ADRA2A gene
have also been associated with type 2 diabetes.7
To our knowledge, 3 studies have been published investi-
gating the potential role of the ADRA2A 1291-C/G polymorphism
in explaining interindividual differences in antipsychotic-induced
weight gain.
The study by Wang et al,8 in 93 Asian patients with a
follow-up of 14 (SD, 6) months, showed that patients carry-
ing the 1291-G/G genotype experienced more weight gain dur-
ing treatment with clozapine than did carriers of the 1291-C/C
genotype (8.5 [SD, 7.2] kg vs 2.8 [SD, 6.1] kg, respectively;
P = 0.023). The 1291-GG genotype or carriership of the vari-
ant G allele was also associated with a more than 7% increase
in body weight during treatment with clozapine (odds ratio
[OR], 4.21; 95% conﬁdence interval [CI], 1.58Y11.19; and OR,
3.45; 95% CI, 1.87Y6.35, respectively). The study by Park et al,9
in 62 Asian patients with a minimum follow-up of 3 months,
showed that patients carrying the G allele more often experi-
enced a more than 10% increase in body weight during treat-
ment with olanzapine (OR, 2.58; 95% CI, 1.21Y5.51). A recent
study by Sickert et al,10 in 129 patients with a follow-up of
6 to 14 weeks, showed that European Americans carrying the
1291-C allele gained more weight compared with subjects ho-
mozygous for the G allele (3.7 [SD, 4.1] kg vs 0.2 [SD, 2.9] kg,
respectively; P = 0.01). These results suggest that ethnicity may
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play a role in the effect of the ADRA2A 1291-C/G polymorphism
on antipsychotic-induced weight gain, with the 1291-G allele
being protective for weight gain in whites and the 1291-C allele
being protective for weight gain in Asians. A basis for this dis-
crepancy between ethnicities may lie in a differential gene ex-
pression caused by genetic and/or environmental factors.
To our knowledge, no studies investigating the possible
association between the ADRA2A 1291-C/G polymorphism and
prevalence of the metabolic syndrome have been published.
The primary objective of this study was to investigate the
association between the ADRA2A 1291-C/G polymorphism and
prevalence of the metabolic syndrome in patients using anti-
psychotics. Secondary objectives were associations between the
ADRA2A 1291-C/G polymorphism and individual parameters




This study included patients from 3 pooled comparable
patient populations. Two of these populations (n = 114 and
n = 170) were used before in previous studies investigating the
association between HTR2c polymorphisms and antipsychotic-
induced metabolic syndrome. The study designs of these studies
have been described in detail elsewhere.11Y13 The third sample
(n = 186) came from an ongoing BPharmacotherapy Monitoring
and Outcome Survey[ (PHAMOUS). PHAMOUS is an initia-
tive from the Rob Giel Research Centre, a number of mental
health care institutions, and the Department of Pharmacotherapy
and Pharmaceutical Care from the University of Groningen.
PHAMOUS combines a yearly somatic screening with routine
outcome assessment in patients using antipsychotics. Risk fac-
tors for cardiovascular and metabolic complications are moni-
tored, and effectiveness of antipsychotic treatment is evaluated
in this survey, with the goal of improving health care for people
with psychosis. Patients included in this study originated from
the northern part of The Netherlands. A detailed description of
the study design can be found on www.phamous.eu (Dutch).
Design and Patients
A cross-sectional design was used to assess the association
between ADRA2A 1291-C/G genotype and the metabolic syn-
drome. Patients were eligible for inclusion in this study if they
were 18 years or older and with a diagnosis of schizophrenia,
schizoaffective or schizophreniform disorder, or psychotic dis-
order. After complete description of the study to the patients,
written informed consent was obtained, and blood was drawn.
Outcome Measures
Primary end point of the study was the presence of the
metabolic syndrome. The metabolic syndrome was deﬁned ac-
cording to the new deﬁnition by the National Cholesterol Edu-
cation Program’s Adult Treatment Panel IIIa (ATPIIIa).14 The
metabolic syndrome was diagnosed in all patients when 3 or
more of the following 5 metabolic criteria were met: waist cir-
cumference 102 cm or greater (male) or 88 cm or greater
(female); triglycerides 1.7 mmol/L or greater or use of a ﬁbrate;
high-density lipoprotein (HDL) cholesterol less than 1.0 mmol/L
(male) or less than 1.3 mmol/L (female) or use of a statin; blood
pressure 130/85 mm Hg or greater or use of an antihypertensive
drug; and ﬁnally fasting glucose 5.6 mmol/L or greater or he-
moglobin A1c (HbA1c) greater than 6.1% or use of an antidi-
abetic. Hemoglobin A1c was used when fasting glucose level
data were not available. The cutoff value used for HbA1c is based
on a review by Bennett et al.15 With respect to triglyceride-
lowering therapy or HDL-increasing therapy, a choice was made
to allocate ﬁbrates speciﬁcally to the triglyceride category and
statins to the HDL category. Allocating both ﬁbrates and statins
to both triglyceride and HDL categories would have led to an
overestimation of the metabolic syndrome, because treatment
with a statin or a ﬁbrate would have led to a diagnosis of the
metabolic syndrome almost immediately. Secondary end points
were the separate metabolic parameters as mentioned above.
Determinants
Primary determinant was the genotype of the 1291-C/G
(rs1800544) polymorphism located in the ADRA2A gene. It
should be noted with regard to ADRA2A polymorphism no-
menclature that, for reasons of clarity, we use the nomencla-
ture and nucleotide numbering at the genomic level according
to the guidelines of the Human Genome Variation Society
(www.hgvs.org) as well as the Btraditional[ nomenclature and
numbering used in previous publications. We regarded the
1291-G allele as the dominant allele, based on the studies by
Wang et al,8 Park et al,9 and Sickert et al.10
DNA Isolation and Genotyping
Genomic DNA of patients was isolated from EDTA blood
using the X-tractor Gene (Corbett Robotics; Corbett Life Sci-
ence, Westburg, Leusden, The Netherlands) with X-tractor Gene
Liquid Sample Reagent Pack (XTR1, Sigma-Aldrich, Westburg,
Leusden, The Netherlands).
Rs1800544 was determined with allelic discrimination
using a predeveloped assay (C_7611979_10; Applied Biosys-
tems, Nieuwerkerk a/d IJssel, The Netherlands) according to a
standard protocol provided by Applied Biosystems. The reaction
was carried out in TaqMan universal polymerase chain reaction
master mix (Applied Biosystems) in a TaqMan 7500 apparatus.
The genotyping of this assay was conducted blind to the clinical
status of the patients.
Data Analyses and Statistics
The association between the metabolic syndrome or the
individual metabolic parameters and the ADRA2A genotype,
or presence or absence of the ADRA2A 1291-G allele, was
investigated with logistic regression. Data were investigated
for potential confounding effects of age, HTR2c rs1414334
and rs3813929 genotypes, ethnicity, Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV) diag-
nosis, sex, and antipsychotic drugs prescribed. We included
these variables in the multivariate model if they were univariately
associated with the primary end point metabolic syndrome at a
signiﬁcance level of P G 0.20.16 Unless otherwise stated, results
are expressed as adjusted ORs. More exploratory analyses in-
cluded a stratiﬁed analysis for individual antipsychotic drugs
used at the moment of evaluation as well as an investigation of
the association between the 1291-C/G polymorphism and the
metabolic syndrome in a small group of schizophrenic patients
not currently using antipsychotic drugs. P e 0.05 or less was
regarded as signiﬁcant. Data were analyzed using SPSS 17.0
(SPSS Inc, Chicago, Ill).
RESULTS
In total, 497 patients were recruited for this study. Twenty-
seven patients did not take any antipsychotic drug at the moment
of evaluation, and data from these patients were used only in the
exploratory analysis. Therefore, the data from 470 patients were
used for primary data analysis.
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Most patients were male (68%), with a diagnosis of schizo-
phrenia (78%) or schizoaffective disorder (17%), with a mean
age of 38 (SD, 10) years. Prevalence of the metabolic syndrome
was 39%.
Of these patients, 442 were of white origin, 14 were of
Asian origin, 9 were of African origin, and the remainder was
of unknown origin. Olanzapine (n = 106 [23%]), risperidone
(n = 103 [22%]), and clozapine (n = 102 [22%]) were the
most frequently prescribed atypical antipsychotic drugs. The
remaining 23% of the patients used aripiprazole (n = 21), que-
tiapine (n = 12), or typical antipsychotics (n = 69) or used a
combination of antipsychotics (n = 57).
The ADRA2A 1291-CC genotype was most prevalent
(51%), followed by the 1291-CG (41%) and 1291-GG genotypes
(8%). Genotype frequencies of the 1291-C/G polymorphism did
not deviate from those expected under Hardy-Weinberg equi-
librium (P = 0.59).
Ethnicity, DSM-IV diagnosis, carriership of the variant
HTR2C rs1414334 C allele, age, sex, and prescribed antipsy-
chotic drug were associated with the metabolic syndrome at a
P G 0.20 signiﬁcance level and were therefore included as cov-
ariates in the multivariate analysis. We did not ﬁnd any con-
founding effects of statin and/or ﬁbrate use. Multivariate analysis
using only the data from patients of white origin did not inﬂuence
the results either.
Table 1 shows that the ADRA2A 1291-C/G polymorphism
was not signiﬁcantly associated with an increased risk for the
metabolic syndrome in patients using antipsychotics. Analysis
based on genotypes as well as carriership of the variant G allele
did not show a signiﬁcant association with the metabolic syn-
drome, although the point estimate decreases by the number of
variant 1291-G alleles.
Table 2 shows that an analysis of the association between
the ADRA2A polymorphism and the 5 components of the met-
abolic syndrome showed a trend for an association with lower
triglyceride levels. Carriership of the variant G allele was protec-
tive for reaching the triglyceride cutoff point of 1.7 mmol/L
(OR, 0.67; 95% CI, 0.44Y1.00; P = 0.05).
A stratiﬁed analysis for the individual antipsychotic drugs
showed no association or trend between carriership of the vari-
ant 1291-G alleles and prevalence of the metabolic syndrome in
any of the antipsychotics (Table 3).
The exploratory analysis in the group of schizophrenic
patients not currently using any antipsychotic drugs (n = 27, with
25 patients evaluable) showed that patients carrying the vari-
ant 1291-G allele had a lower chance of having the metabolic
syndrome than patients not carrying the variant 1291-G allele
(nonadjusted OR, 0.10; 95% CI, 0.01Y0.97; P = 0.047). This
lowered risk was still signiﬁcant after correction for the 2 sig-
niﬁcant (P G 0.2) covariables, age and sex (OR, 0.05; 95%
CI, 0.003Y0.97; P = 0.048; Table 1).
DISCUSSION
In this study, we did not ﬁnd a signiﬁcant association be-
tween the 1291-C/G polymorphism in the ADRA2A gene and
prevalence of the metabolic syndrome in psychiatric patients
using antipsychotics. However, we found that the point estimate
TABLE 1. ADRA2A 1291C/G Genotype and Metabolic Syndrome
Genotype Patients (n = 408) Metabolic Syndrome Crude OR* (95% CI; P) Adjusted OR*† (95% CI; P)
Patients with antipsychotics
1291-CC 215 43% 1 1
1291-GC 165 36% 0.74 (0.49Y1.13; 0.17) 0.77 (0.48Y1.23; 0.27)
1291-GG 28 29% 0.54 (0.23Y1.27; 0.16) 0.49 (0.18Y1.33; 0.16)
1291-GG+GC‡ 193 35% 0.71 (0.48Y1.06; 0.095) 0.73 (0.49Y1.15; 0.18)
Patients without antipsychotics (n = 25)§
1291-GG+GC 9 11%|| 0.097 (0.01Y0.97; 0.047) 0.05 (0.003Y0.97; 0.048)
*Data were analyzed with the common genotype (1291-CC) as reference.
†Data were adjusted for age, sex, carriership of variant HTR2c rs1414334 C allele, ethnicity, DSM-IV diagnosis and prescribed antipsychotic drug.
‡Analysis for carriership of the variant allele.
§Data could be investigated only for an association between carriership of the variant allele and the metabolic syndrome because of sample size.
||Compared with 56% in group with 1291-CC genotype.
TABLE 2. Association Between Carriership of the Variant 1291-G Allele and Individual ATPIIIa Parameters Contributing to the
Metabolic Syndrome
Determinant* Patients† Crude OR (95% CI; P) Adjusted OR (95% CI; P)‡
HDL cholesterol 440 1.00 (0.69Y1.46; 0.99) 1.07 (0.71Y1.62; 0.75)
Triglycerides 442 0.60 (0.41Y0.88; 0.008) 0.67 (0.44Y1.00; 0.05)
Waist circumference 446 1.18 (0.82Y1.71; 0.38) 1.43 (0.92Y2.21; 0.11)
Hypertension 357 0.93 (0.61Y1.41; 0.73) 0.95 (0.60Y1.52; 0.84)
Glucose 408 0.97 (0.59Y1.61; 0.91) 0.87 (0.49Y1.55; 0.64)
*HDL cholesterol G1.0 mmol/L (male) or G1.3 mmol/L (female) or use of a statin. Triglycerides Q1.7 mmol/L or use of a ﬁbrate. Waist
circumference Q102 cm (male) or Q88 cm (female). Hypertension = blood pressure Q130/85 mm Hg or use of an antihypertensive drug. Glucose =
fasting glucose Q5.6 mmol/L, or HbA1c 9 6.1% or use of an antidiabetic.
†Patient number varies because of missing values.
‡Data were adjusted for age, sex, carriership of variant HTR2c rs1414334 C allele, ethnicity, DSM-IV diagnosis and prescribed antipsychotic drug.
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for an association between the 1291-C/G genotype and the met-
abolic syndrome decreased as the number of variant 1291-G
alleles in the genotype increased (Table 1). This inverse relation is
suggestive for a gene-dose effect, although this was not signiﬁcant
possibly because of the limited power of this study. A trend was
found for an association between the ADRA2A 1291-C/G poly-
morphism and triglyceride levels, in which the variant 1291-G
allele was protective for reaching the triglyceride cutoff point of
1.7 mmol/L (OR, 0.67; 95% CI, 0.44Y1.00; P = 0.05). An ex-
ploratory analysis in a group of patients not currently using
antipsychotics showed a protective effect of carriership of the
variant 1291-G allele on prevalence of the metabolic syndrome
(OR, 0.05; 95% CI, 0.003Y0.97; P = 0.048).
There are some limitations to these results. First, although our
sample is relatively large with 470 patients, still only 37 patients
carrying the 1291-G/G genotype were included. Because most
effect of the 1291-C/G polymorphism is expected in this group
(Sickert et al,10 Wang et al8), it is possible that the sample size was
too small to ﬁnd signiﬁcant results.
Second, we recognize that a cross-sectional design has its
limitations because data on metabolic parameters of the patients
at the initiation of antipsychotic drug treatment were not avail-
able to us. Therefore, we were unable to analyze data for changes
in these parameters over time related to the use of antipsychotic
drugs.
This limitation makes it difﬁcult to compare our results
to prospective follow-up studies investigating the association
between the ADRA2A 1291-C/G polymorphism and meta-
bolic disturbances (weight gain) in psychiatric patients using
antipsychotics.8Y10
Third, some variables contributing to a patient’s risk of the
metabolic syndrome, for example, smoking behavior, exercise,
and diet, were not taken into account. Fourth, in most of the
patients, no values for fasting plasma glucose were available
in this study. Therefore, we used HbA1c instead, with a cutoff
value of greater than 6.1%. Using HbA1c instead of fasting
glucose possibly has some effect on the diagnosis of the meta-
bolic syndrome, thereby affecting our results. However, the re-
view study by Bennett et al15 showed that a recommended
HbA1c cutoff point of greater than 6.1% had similar accuracy as
fasting plasma glucose 6.0 mmol/L for predicting type 2 diabetes
(sensitivity, 72.7%; speciﬁcity, 94.7%). Based on these results,
and the fact that we did not even see a trend toward a positive
association between the ADRA2A polymorphism and HbA1c,
we believe that using HbA1c instead of fasting plasma glucose
did not inﬂuence our results.
Fifth, although predominantly white, our sample was of
mixed ethnic origin. Ethnicity could be an important confounder
in data analysis because the studies in Asians and whites have
shown opposite results. However, we corrected for ethnicity in
our multivariate analysis, and moreover, using only the data from
white patients (n = 440) did not affect our results.
Waist circumference is one of the most relevant determi-
nants for insulin resistance and cardiovascular morbidity in the
ATPIIIa deﬁnition of the metabolic syndrome.17,18 Because the
adrenergic >-2a receptor (ADRA2A) has an important function
in lipolysis and therefore in waist circumference, as was shown
by Garenc et al,6 one would expect an association between the
ADRA2A 1291-C/G polymorphism and waist circumference
and the metabolic syndrome. In this study, we could not ﬁnd
these associations, although the mean waist circumference did
decrease with an increasing number of variant G alleles in the
genotype (CC: 101 cm, CG: 100.0 cm, GG: 98.0 cm). However,
because the average SD was around 14 cm, these differences
were not signiﬁcant. The trend we found for an association be-
tween the 1291-C/G polymorphism and triglyceride levels is
suggestive for an association with lipolysis nevertheless (Table 2).
It is possible that drugs with an antagonistic action for
ADRA2As, such as antipsychotics, mask the effects of the
1291-C/G genotype (protective effect of the 1291-G allele) on
waist circumference and prevalence of the metabolic syndrome.
This would explain why we found no association in the group of
patients currently using antipsychotics, but did ﬁnd an associa-
tion in the group of patients not currently using antipsychotics.
Following this lead, we divided our study sample in a group
of patients using antipsychotics with a high afﬁnity for the >-2
receptors (clozapine, quetiapine, and risperidone) and a group of
patients using antipsychotics with a lower afﬁnity for the >-2
receptors based on the study by Matsui et al.19 The resulting
analysis showed no association between the 1291-C/G poly-
morphism and prevalence of the metabolic syndrome (results
not shown).
It is possible that even antipsychotics with a lower afﬁnity
for >-2a receptors still mask the protective effect of the 1291-G
allele, but given the fact that the Bantipsychotic-naive[ group of
patients was small, the results found in this group could also be a
type I error. To further explore the impact of the 1291-C/G
polymorphism on lipolysis and prevalence of the metabolic
syndrome, we are currently investigating this association in a
larger antipsychotic-naive population.
This is the ﬁrst study in which the association between the
ADRA2A 1291-C/G polymorphism and prevalence of the
metabolic syndrome was investigated. Insight in the factors re-
sponsible for the metabolic syndrome can have implications for
daily clinical psychiatric practice, because there is a strong as-
sociation between the metabolic syndrome and cardiovascular
TABLE 3. Association Between Carriership of the Variant 1291-G Allele and the Metabolic Syndrome for Individual Antipsychotics
Antipsychotic n MS Crude OR (95% CI) Adjusted OR* (95% CI)
Clozapine 91 44% 0.89 (0.47Y1.71) 0.99 (0.47Y2.07)
Olanzapine 99 33% 0.50 (0.23Y1.08) 0.49 (0.18Y1.39)
Risperidone 87 31% 1.03 (0.48Y2.19) 0.44 (0.15Y1.32)
Quetiapine 16 38% 1.30 (0.25Y6.74) NA
Aripiprazole 10 30% 0.21 (0.01Y3.13) NA
Typical antipsychotic 56 45% 1.03 (0.46Y2.30) 1.37 (0.49Y3.89)
Multiple antipsychotic 49 33% 0.39 (0.13Y1.16) 0.32 (0.09Y1.22)
*Data were adjusted for age, sex, carriership of variant HTR2c rs1414334 C allele, ethnicity, and DSM-IV diagnosis.
MS indicates metabolic syndrome; NA, not applicable.
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morbidity and mortality. A pharmacogenetic tool to predict a
patient’s chance of developing the metabolic syndrome would
be helpful in psychiatric practice because this could identify
patients at risk, offering an opportunity to choose an alternative
treatment.
In conclusion, this study shows that the ADRA2A 1291-C/G
polymorphism does not seem to be a strong predictor for long-
term occurrence of the metabolic syndrome in patients using
antipsychotics. However, the use of antipsychotics with antago-
nistic ADRA2A activity may mask the possible protective effect
of the 1291-G allele as shown in patients not currently using
antipsychotics.
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